AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 43 min read$MIRM

Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance

Mirum Pharmaceuticals (MIRM) raised its full-year guidance, citing broad-based growth, with adult PFIC as the biggest driver. Q3 saw elevated R&D expenses and minimal Takeda purchases of Livmarli. The company faces regulatory uncertainty for Belixabat and potential revenue headwinds. Management expects continued quarterly revenue growth of $10M-$15M through 2027, with key data readouts planned for Q1 2027.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 7:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MIRMBullishMed
01

Why it matters

Guidance raise is the primary new information; other pipeline details are follow‑on context.

02

Market read

Guidance lift is a material catalyst for Mirum's stock and may influence peer biotech valuations.

03

What to watch

R&D spend remains high at ~50% of revenue, which could pressure near‑term margins.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Mirum discussed multiple pipeline updates, R&D spending, and upcoming NDA submissions while highlighting raised guidance.

Company-level read

Ticker impact

$MIRMBullishHigh confidence
Context

Mirum Pharmaceuticals raised its full-year guidance during its Q3 2026 earnings call, citing strong portfolio growth and adult PFIC as the main driver.

Expected impact

likely upward pressure as investors price in stronger outlook

Evidence & confidence

Guidance lifts are a direct catalyst that can move the stock immediately.

Market effects

Sector

Positive outlook may boost sentiment in the rare‑disease biotech sector.

Regional

US biotech investors may see a rally in similar pipeline companies.

Global

Limited to biotech niche; no broad market effect.

Counterpoint

What could challenge this read

If guidance relies heavily on adult PFIC, any regulatory setback could reverse the upside.

Key entities

  • company
    Mirum Pharmaceuticals Inc

    US‑listed biotech focused on rare liver diseases.

Read at source← All news

StoryMirum Pharmaceuticals reports Q3 2026 results, FDA approval of ATEBRIOZ and raises full‑year guidance

Also covered by

5 outlets

Related articles

NOV 4
$MIRMMed

H.C. Wainwright raises Mirum Pharmaceuticals price target to $202

H.C. Wainwright raised its price target on Mirum Pharmaceuticals (MIRM) to $202, citing strong Q3 2026 sales of $185.7M, up 40% YoY. LIVMARLI sales reached $133.4M, up 45% YoY. The company's revenue grew 44% over the last year with an 82% gross margin. Despite a wider-than-expected loss, other analysts also raised price targets, noting commercial strength and pipeline progress.

investing.com2 min
NOV 4
$MIRMMed

Citizens raises Mirum Pharmaceuticals price target on pipeline progress

Citizens raised its price target for Mirum Pharmaceuticals (MIRM) to $167 from $144, citing Livmarli's growth and a diversified pipeline. The company reported 44% revenue growth and 81.7% gross margin. Mirum's Q3 2026 revenue of $185.7M beat estimates, though it posted a wider-than-expected loss per share. The stock has a Strong Buy consensus with targets ranging from $118 to $200.

investing.com2 min
NOV 4
$MIRMHighAI 8/10

Mirum Pharmaceuticals Q3 Earnings Call Highlights

Mirum Pharmaceuticals reported Q3 revenue growth of $10M-$15M, expecting this trend to continue through 2027. ATEBRIOZ, approved in September, began U.S. launch with positive early feedback. The company anticipates multiple regulatory submissions in 2027. Mirum ended Q3 with $500M in cash and expects R&D expenses to decline to 10% of revenue long-term.

finance.yahoo.com3 min
NOV 3
$MIRMMedAI 8/10

Mirum Pharmaceuticals Q3FY26 Results: Sales rise 40%, guidance beats estimates

Mirum Pharmaceuticals reported Q3FY26 net product sales of $186M, up 40% YoY. The company raised full-year guidance to $715M-$720M, beating estimates. Livmarli drove growth, with adult PFIC as a key driver. Operating expenses were $245M, with R&D at 50% of revenue. Cash position is ~$500M. The company plans several regulatory milestones and expects cash flow positivity next year.

scanx.trade5 min